
|Videos|February 11, 2019
Expert Explains the Greatest Challenge in Treating Patients With MDS and AML
Author(s)Christopher R. Cogle, MD
Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes and acute myeloid leukemia.
Advertisement
Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Both MDS and AML are very heterogenous diseases where a patient has multiple MDS or AML clones, Cogle says. In his research, he found that there were hundreds of genomic abnormalities in each patient.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sac-TMT Plus Pembrolizumab Beats Chemo-Immunotherapy in PD-L1–Negative NSCLC
2
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
3
Vitamin D Use Tied to Longer Treatment-Free Survival in Early-Stage CLL
4
The Intelligent Medical Record: Reimagining the Future of Oncology Care
5

































